


September 16, 2008

Contact: Garry Carneal
Phone: (410) 777-5310
Email: info@preventingcolorectalcaner.org
Website: www.preventingcolorectalcaner.org



Salix Pharmaceuticals Becomes Founding Corporate Sponsor of the National Coalition for Quality Colorectal Cancer Screening and Care

Salix Supports Coalition's Mission to Increase Screening for and Education about Colorectal Cancer

Annapolis, Maryland / September 16, 2008. The National Coalition for Quality Colorectal Cancer Screening and Care announced that Salix Pharmaceuticals, Ltd. has become a Founding Corporate Sponsor supporting the Coalition.

"We are pleased that Salix has become an active supporter of the Coalition, remarks Steven J. Morris, MD JD FACP FACG, Coalition Board Chairperson and CEO of Atlanta Gastroenterology Associates, LLC. He adds that "Going forward, Salix's partnership with our nonprofit educational group is a good fit because of Salix's interest in treating gastrointestinal diseases in combination with the Coalition's focus that encourages colonoscopies and similar treatment interventions."

Michael Freeman, Associate Vice President, Corporate Communications, Salix Pharmaceuticals, Inc. states, "Salix is looking forward to supporting the Coalition. Getting the word out about colorectal screenings and treatments is critical to promoting good population-based health and protecting individual patients."

Dr. Stanford Plavin, Coalition Board Vice-Chairperson and Managing Partner of Ambulatory Anesthesia of Atlanta, P.C. explains "The Coalition supports a sustained effort of collaboration, research, and education geared to both key public and private stakeholders -- with the primary goal of reducing the incidence of colorectal cancer. The Coalition offers a unique and important forum to bring all of the stakeholders together to identify, discuss and promote meaningful and effective health care strategies."

Regarding Salix, Freeman notes "Salix is committed to becoming the leading U.S. specialty pharmaceutical company licensing, developing and marketing innovative products to health care professionals to prevent or treat gastrointestinal disorders in patients."

Morris elaborates "Salix joins several other organizations that have joined the Coalitions efforts in recent months as a 'Founding Corporate Sponsor.' Our hope is that the Coalition will serve as a respected resource and objective voice representing quality-based, colorectal screening and treatment options for patients."

To learn more about the activities of the Coalition, visit www.preventingcolorectalcaner.org. You can contact the Coalition at (866) 461-9296 (toll free) or via email to info@preventingcolorectalcaner.org.

* * * * *

Headquartered in Annapolis, Maryland, **the National Coalition for Quality Colorectal Cancer Screening & Care** (www.preventingcolorectalcaner.org) preserves the tradition of safe, comfortable and quality-based medicine. The Coalition is a nonprofit advocacy organization with its primary mission to educate both public and private stakeholders about the opportunities to reduce the incidence of colorectal cancer through promoting effective screening, prevention and care options for patients.

Headquartered in Raleigh, North Carolina, **Salix Pharmaceuticals, Ltd.**, (www.salix.com) develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. Salix's strategy is to in-license late-stage or marketed proprietary therapeutic drugs, complete any required development and regulatory submission of these products, and market them through the Company's gastroenterology specialty sales and marketing team.